Floatz logo

Revacept

Thrombosis

AdvanceCor GmbHPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Thrombosis cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Shanghai Zhongshan Hospital
Phase 4BBB
Acetylsalicylic Acid
China National Center for Cardiovascular Diseases
Phase 4BBB
Apixaban
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Phase 4BB
Dabigatran
St. Antonius Hospital
Phase 4BB
WARFARIN
China National Center for Cardiovascular Diseases
Phase 4BB

View all 24 →

Same molecule, other indications

Revacept is also rated in:

carotid stenosisDormant
B
Indicative ·
57 / 100
View asset →
atherosclerosisDormant
B
Indicative ·
57 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →